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Abstract
Proteasomes play a fundamental role in intracellular protein degradation and therewith regulate a variety of cellular
processes. Exposure of cells to (pro)inflammatory cytokines upregulates the expression of three inducible catalytic
proteasome subunits, the immunosubunits, which incorporate into newly assembled proteasome complexes and alter the
catalytic activity of the cellular proteasome population. Single gene-deficient mice lacking one of the three immunosubunits
are resistant to dextran sulfate sodium (DSS)-induced colitis development and, likewise, inhibition of one single
immunosubunit protects mice against the development of DSS-induced colitis. The observed diminished disease
susceptibility has been attributed to altered cytokine production and CD4+ T-cell differentiation in the absence of
immunosubunits. To further test whether the catalytic activity conferred by immunosubunits plays an essential role in CD4+
T-cell function and to distinguish between the role of immunosubunits in effector T-cells versus inflamed tissue, we used a
T-cell transfer-induced colitis model. Naı¨ve wt or immunosubunit-deficient CD4+ T-cells were adoptively transferred into
RAG12/2 and immunosubunit-deficient RAG12/2 mice and colitis development was determined six weeks later. While
immunosubunit expression in recipient mice had no effect on colitis development, transferred immunosubunit-deficient T-
cells were more potent in inducing colitis and produced more proinflammatory IL17 than wt T-cells. Taken together, our
data show that modifications in proteasome-mediated proteolysis in T-cells, conferred by lack of immunosubunit
incorporation, do not attenuate but enhance CD4+ T-cell-induced inflammation.
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Introduction
The immune system senses pathogens through pattern recog-
nition receptors that bind specific pathogen-associated molecular
patterns. Ligand binding induces a signaling cascade downstream
of the receptor that activates a specific transcriptional program,
allowing the immune system to respond efficiently to the invading
microorganisms. The proteasome, an abundant cellular protease
complex, plays an essential role in those signaling pathways, as the
activation of many signaling molecules is regulated by the timely
degradation of other molecules in the signaling complex. So
depends the activation of the transcription factor NFkB on
phosphorylation, ubiquitylation and subsequent proteasome-me-
diated degradation of its inhibitor IkB [1]. IkB degradation
exposes a nuclear localization sequence in NFkB, allowing it to
translocate to the nucleus and to initiate the expression of,
amongst others, (pro)inflammatory cytokines [1–3]. Another
function of proteasomes, during infection with intracellular
pathogens, is the processing of pathogen-derived antigens into
peptides that can be presented by MHC class I molecules on the
cell surface, allowing CD8 T-cells to detect and react to the
presence of intracellular pathogens (for review see [4]). Thus,
proteasome activity plays an essential role at different stages of
pathogen-specific immune responses.
Proteasomes consist of a barrel-shaped catalytic core particle,
the 20S proteasome, and one or more regulatory particles (for
review see [5]). The enzymatic activity of the 20S proteasomes is
exerted by three b subunits, located in the inner two rings of the
20S complex, which exhibit caspase-like (b1), trypsin-like (b2) and
chymotrypsin-like activity (b5). Exposure of cells to type 1 and type
2 interferons or TNFa induces the expression of three facultative
subunits, b1i/LMP2, b2i/MECL-1 and b5i/LMP7, which pref-
erentially incorporate into newly assembled proteasome complexes
and thus, when expressed, replace their constitutive homologues in
the cellular proteasome population [5]. In addition, in particular
cells of the hematopoietic lineage express different quantities of the
three facultative subunits and, therefore, often contain so called
‘‘mixed’’ proteasomes, containing the constitutive and one or more
inducible b subunits [5,6]. Due to altered cleavage preferences,
proteasomes containing the facultative subunits (named immuno-
proteasomes) are more suited to generate high affinity MHC class
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I ligands than constitutive proteasomes, containing the b1, b2 and
b5 subunits [5,7,8]. As a consequence, pathogen-specific CD8+ T-
cell responses often target immunoproteasome-generated peptides
[5,8,9]. Immunoproteasomes have further been shown to protect
cells from interferon-induced oxidative stress, by efficient removal
of aggregates of oxydant-damaged, polyubiquitylated unfolded
nascent proteins [10,11] and immunoproteasome expression in the
peripheral tissues was found to protect against early forms of CD8+
T-cell-mediated autoimmune diseases [7,10]. In specific, we
showed that irradiated and BM reconstituted, b2i/MECL-
1&b5i/LMP7-deficient recipient mice developed latent forms of
CD8+ T-cell-mediated autoimmune diseases, such as insulin-
dependent diabetes mellitus and diabetes insipidus [7]. This could
be explained by altered MHC class I antigen processing of tissue
antigens in inflamed immunosubunit-deficient tissue, in particular,
since adoptive transfer of CD4+ T-cell depleted splenocytes from
diseased mice conferred the disease phenotype onto RAG12/2
mice that also lacked immunosubunit expression, but not onto
RAG12/2 mice that expressed the immunosubunits [7]. Alterna-
tively, enhanced death in immunosubunit-deficient tissues follow-
ing irradiation [10] may have led to presentation of tissue antigens
in the draining lymph nodes and thus may have induced priming
of auto-reactive CD8+ T-cells.
In hematopoetic cells, expression of the immunosubunits
supports the production of many cytokines. [12–14]. Based on
the latter observations, immunoproteasomes have been proposed
to drive inflammatory processes, an assumption that is supported
further by the anti-inflammatory effects of proteasome subunit-
specific inhibitors [14]. The role of immunoproteasomes in
inflammatory diseases has been investigated in further detail in
different mouse models of colitis [15–17]. These studies showed
that inflammatory disease was accompanied by high levels of
immunosubunit expression in the inflamed tissue, with cellular
infiltration and expression of inflammatory cytokines [15,16].
Inhibition of activity of the proteasome subunit LMP7/b5i or of
both LMP7/b5i and b5 largely prevented DSS-induced colitis,
and was associated with reduced quantities of inflammatory
cytokines [14–16]. Notably, a deficiency of b5i/LMP7, in mice
lacking the gene encoding this subunit, protected from DSS-
induced colitis [15,16]. This was attributed to diminished
processing of the transcription factor NFkB, which initiates
cytokine transcription, in hematopoietic cells by Schmidt et al.
[15]. Groettrup and coworkers [17], however, reported a reduced
differentiation of ‘‘proinflammatory’’ Th1 and Th17 cells and
enhanced differentiation of regulatory T-cells (Tregs) in b5i/
LMP72/2 mice, suggesting that altered T-cell differentiation may
explain for the ameliorating effects of b5i/LMP7 deficiency in
development of DSS-induced colitis. The last authors also showed
that LPS or anti-CD3 stimulated spleen cells of wt and b5i/
LMP72/2 mice produce similar amounts of IL-6, IFNy and IL-17
[14,16], arguing against a direct effect of LMP7 on the production
of those cytokines. Taken together, these data establish an
important regulatory role for the immunosubunit b5i/LMP7 in
inflammatory disease, but the underlying molecular mechanism
remains poorly understood. In addition, the protective effects of
b5i/LMP7 deficiency in inflammatory disease are remarkable in
light of the observed importance of immunoproteasomes in
clearing potentially toxic protein aggregates in cytokine-exposed
cells [10].
To further investigate the role of proteasome immunosubunits
in autoimmune, inflammatory disease, we analyzed T-cell-induced
colitis development in RAG1 gene-deficient mice compared to
RAG1&b2i/MECL-1&b5i/LMP7-deficient mice, in a T-cell
transfer model. Using this model, we were able to distinguish
between disease modifying effects of immunosubunit expression in
inflamed tissue and in effector T-cells, respectively.
Results
b2i/MECL-1&b5i/LMP7 Deficiency does not Protect
against T-cell Transfer-induced Colitis
Previous studies have shown that the absence or the inhibition
of the immunosubunit b5i/LMP7 protects mice against develop-
ment of DSS-induced colitis, which was attributed to diminished
transcription of (pro)inflammatory cytokines or to diminished Th1
and Th17 and enhanced Treg cell differentiation [15,17]. To
determine to which extent the absence of immunosubunit
expression in effector T-cells versus in inflamed tissue confers
resistance to colitis development, we employed a well-established
T-cell transfer-induced colitis model [18–20]. Purified naı¨ve wt or
b2i/MECL-1&b5i/LMP7–deficient T-cells were transferred into
RAG1-gene-deficient mice or b2i/MECL-1&b5i/LMP7 deficient
mice that had been backcrossed onto the RAG12/2 background.
Six weeks after cell transfer, mice were sacrificed and colitis
development was determined by histological scoring (for criteria,
see Materials and Methods). As expected, RAG-12/2 mice
transferred with wt CD4+ T-cells developed colitis (Figure 1A,
Figure S1) and so did transferred RAG12/2b2i/MECL-12/2b5i/
LMP72/2 mice, with similar severity as RAG12/2mice. Surpris-
ingly, b2i/MECL-12/2b5i/LMP72/2 CD4+ T-cells also caused
colitis, both in RAG12/2 and RAG12/2b2i/MECL-12/2b5i/
LMP2/2 mice (Figure 1A, Figure S1). Histological scores in mice
that received b2i/MECL-1&b5i/LMP7-deficient T-cells were
even higher than in recipients of wt CD4+ T-cells (Figure 1B–D,
Figure S1), with significant differences in the proximal colon
(Figure 1B, Figure S1). Thus, neither a lack of proteasome
immunosubunit expression in effector T-cells nor in the inflamed
tissue conferred resistance to development of T-cell transfer-
induced colitis.
To determine how colitis development in RAG12/2 mice and
RAG12/2b2i/MECL-12/2b5i/LMP72/2 mice correlated with
expansion of transferred, naı¨ve CD4+ T-cells, spleens of these mice
were harvested and analyzed. Total numbers of splenocytes were
lower in transferred RAG12/2b2i/MECL-12/2b5i/LMP72/2
mice than in transferred RAG12/2 mice (Figure 2A), consistent
with the reduced spleen size and numbers of total splenocytes often
observed in b2i/MECL-1&b5i/LMP7-deficient compared to wt
mice (D.Z. and A.S., unpublished observations). Analysis of the
splenic CD4+ T-cell populations by flow cytometry revealed no
major differences in percentages of CD4+ T-cells between the
different mouse groups (Figure 2B), but total numbers of CD4+ T-
cells were higher in mice transferred with b2i/MECL-1&b5i/
LMP7-deficient CD4+ T-cells than in recipients of wt CD4+ T-cells
(Figure 2C), which was in direct correlation with the enhanced
severity of inflammation in the colon (Figure 1). These data show
that b2i/MECL-1&b5i/LMP7-deficiency does not impair the
proliferative potential of CD4+ T-cells.
Enhanced Induced (i)Treg Differentiation and Elevated
Levels of IL17 in Colitic Mice that Received b2i/MECL-
1&b5i/LMP7-deficient CD4+ T-cells
b5i/LMP7-deficient mice are resistant to development of DSS-
induced colitis, due to reduced NFkB activation or to altered
CD4+ T-cell differentiation, which both may dampen the
production of (pro)inflammatory cytokines [15,17]. Intracellular
staining of FoxP3 in spleen-derived CD4+ T-cells of mice with T-
cell transfer-induced colitis (Figure 2D, E) showed enhanced
numbers and percentages of FoxP3pos cells, i.e. iTregs, in mice that
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had received b2i/MECL-1&b5i/LMP7-deficient CD4+ T-cells.
On the other hand, deficiency of b2i/MECL-1&b5i/LMP7 in
recipient mice had no effect on iTreg differentiation (Figure 2D,
E).
Analysis of cytokine expression in TCR-activated splenic T-cells
by RT-PCR demonstrated enhanced quantities of IL17 mRNA in
recipients of b2i/MECL-1&b5i/LMP7-deficient CD4+ T-cells
(Figure 3A), while expression levels of IFNy, IL10 and TNFa did
not differ between the different mouse groups (Figure 3B–D).
Thus, both iTregs and IL17-producing cells were more frequent in
spleens of colitic mice that had been transferred with b2i/MECL-
1&b5i/LMP7-deficient CD4+ T-cells than in mice that had
received wt CD4+ T-cells.
Discussion
Previous studies have shown that proteasome immunosubunits
may modify host susceptibility to autoimmune and inflammatory
diseases at multiple levels, i.e. by altering MHC class I antigen
processing in inflamed tissues, by modulating the ability of cells to
cope with cell stress and by modulating signal transduction and
transcriptional programs in cells, leading to modified T-cell
differentiation [7,10,15,17]. We have used a murine model of T-
Figure 1. Colitis development in T-cell transferred mice. Flow cytometry-sorted naı¨ve CD4+ T-cells of B6 (WT) or b2i/MECL-12/2b5i/LMP72/
2(IS2/2) mice were transferred into RAG12/2 or RAG12/2b2i/MECL-12/2b5i/LMP72/2 (IS2/2 x RAG12/2) mice and colitis development was
determined 6 weeks by histological scoring of H&E stained tissue samples (see M&M). (A) overall colitis scores, (B) colitis scores in the proximal 2, (C)
mid2, and (D) distal colon sections. Scores for individual mice and means+SEM (n = 3–6 per group) are depicted. *p,0.05. Data are representative of
two independent experiments.
doi:10.1371/journal.pone.0095378.g001
Figure 2. CD4 T cells and iTreg cells in mice with T-cell transfer-induced colitis. Splenocytes of mice with T-cell transfer-induced colitis,
harvested six weeks after T-cell transfer, were stained for CD4 and FoxP3 expression and analyzed by flow cytometry. (A) absolute numbers of
splenocytes; (B, D) percentages, and (C, E) numbers of CD4+ T-cells and CD4+FoxP3+ T-cells in the spleen. Results for individual mice and means+SEM
(n = 3–6 per group) are depicted. *p,0.05.
doi:10.1371/journal.pone.0095378.g002
Immunosubunit-Deficient T-Cells Drive Inflammation
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e95378
cell transfer-induced colitis to further examine the role of the
proteasome immunosubunits in inflammatory diseases. We show
that naı¨ve CD4+ T-cells of mice that lack the two immunosubunits
b2i/MECL-1&b5i/LMP7 cause colitis upon transfer into
RAG12/2 mice, which is more severe than colitis induced by
transfer of naı¨ve wt CD4+ T-cells. Enhanced colitis scores were
associated with enhanced numbers of total splenic CD4+ T-cells,
enhanced frequencies and numbers of iTregs and enhanced IL17
production. Previous studies in humans and DSS-treated mice
showed that not only immune cells but also inflamed colon tissue
expressed the proteasome immunosubunits [16,21]. In our
experiments, the severity of T-cell transfer-induced colitis did
not differ between Rag12/2 mice and RAG12/2 mice that had
been backcrossed onto an b2i/MECL-1&b5i/LMP7-deficient
background (Figure 1), arguing against a role for immunosubunit
expression in the inflamed gut in colitis development. This is
consistent with prior observations, which showed that transplan-
tation of wt bone marrow rendered b5i/LMP7-deficient mice
susceptible to development of DSS-induced colitis [15]. Thus, in
the T-cell transfer model, b2i/MECL-1&b5i/LMP7-deficiency in
transferred, naı¨ve CD4+ T-cells enhances colitis development in
RAG12/2 mice, whereas immunosubunit-deficiency in the
targeted gut does not have any effect on colitis development.
Studies by different groups have demonstrated that proteasomes
play an important role in cytokine production and that modulation
of proteasome subunit composition may alter cytokine production.
For example, dendritic cells of LMP2-deficient mice produce less
IFNa, IL-6, IL-1b and TNFa following influenza virus infection
than wt dendritic cells [12]. This defect was attributed to the
formation of mixed proteasomes, containing the immunosubunits
b2i/MECL-1 and b5i/LMP7 and the constitutive subunit b1/d,
which may diminish transcription of these cytokines by delaying
NFkB processing in those cells. A diminished transcription of the
same cytokines, IL17 and IL23 was detected also during DSS-
induced colitis in b5i/LMP7-deficient, in b1i/LMP2 deficient-
and in b2i/MECL-1-deficient mice, as well as in mice treated with
selective inhibitors targeting the b5i/LMP7 and b5 subunits or the
b5i/LMP7 subunit only [15,16]. This was accompanied by a
reduced activation of NFkB, in b5i/LMP7-deficient cells [15] and
reduced Th1 and Th17 but enhanced Treg cell differentiation of
CD4+ T-cells in the lamina propria of b5i LMP7-deficient/
inhibitor-treated mice with mild forms of DSS-induced colitis [15–
17]. Following T-cell transfer into RAG22/2 mice, Kalim et al.
[17] further observed a diminished Th1 and Th17 and enhanced
Treg cell differentiation in recipients of b5i/LMP7-deficient CD4+
T-cells, suggesting that differences in T-cell differentiation explain
for the relative resistance of inhibitor-treated or b5i/LMP7-
deficient mice to development of DSS-induced colitis.
In agreement with Kalim et al [17], we observe an enhanced
differentiation of naı¨ve immunosubunit-deficient CD4+ T-cells
into iTregs in adoptively transferred RAG12/2 mice. However,
we also find that these iTregs fail to protect the transferred mice
against colitis development. Thus, recipients of b2i/MECL-
1&b5i/LMP7-deficient T-cells develop colitis six weeks after T-
cell transfer, with even higher histological scores and higher
quantities of IL17a in the spleens than detected in recipients of wt
CD4+ T-cells, despite enhanced numbers and frequencies of
iTregs. On the other hand, FACS-purified Tregs derived from
b2i/MECL-1&b5i/LMP7-deficient, immunocompetent mice sup-
press CD4+ T-cell-induced colitis upon cotransfer (not shown),
indicating that b2i/MECL-1&b5i/LMP7-deficiency does not
disable Treg function. Interestingly, in a recent publication, Basler
et al. [22] showed that both b5i/LMP7-deficient and wt mice
develop experimental autoimmune encephalitis (EAE) following
immunization with the MOG35–55 peptide. Disease intensity did
not significantly differ between mouse groups in this study, but was
found to be more intense in b5i/LMP7-deficient mice by Seifert
et al. [10], using the same model. As Th17 cells play a central role
in the onset and maintenance of EAE, these studies indicate that
an exchange of b5i/LMP7 for b5 in T-cells does not diminish T
cell-induced inflammatory disease. Moreover, specific inhibition of
b5i/LMP7 ameliorated peptide-immunization-induced EAE in wt
mice, while specific inhibition of the constitutive proteasome
subunit b5 ameliorated EAE in LMP7-deficient mice [22],
Figure 3. Cytokine expression in mice with T-cell transfer-induced colitis. Splenocytes of mice with T -cell transfer-induced colitis were
stimulated with anti-CD3 mAb for 4 hrs. mRNA was extracted and cytokine expression was quantified by RT-PCR. Expression of (A) IL17a, (B) IFNy, (C)
IL10, and (D) TNFa relative to 18S rRNA is shown for individual mice per experimental group. Bars represent means+SEM (n= 3–6). *p,0.05. Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0095378.g003
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indicating that the enzymatic activity of the b5/b5i proteasome
active site subunit is critical for CD4+ T-cell function. Taken
together, we conclude that the exchange of b5i/LMP7 for b5 in T
cells does not abolish but may modulate CD4+ T-cell mediated
disease, with aggravating effects on inflammation in case of T-cell
transfer-induced colitis.
While our data show that immunosubunit-deficiency does not
ameliorate T-cell transfer-induced colitis, immunosubunit-defi-
cient mice are protected from DSS-induced colitis [15–17].
Although unlikely, it cannot be ruled out that this discrepancy
between effects in the two models may be explained by the use of
different immunosubunit deficient mice in these studies. While
resistance to DSS-induced colitis was observed in single immuno-
subunit-deficient mice, lacking either b1i/LMP2, b2i/MECL-1 or
b5i/LMP7 [15–17], we used b2i/MECL-1&b5i/LMP7-deficient
T-cells to determine the effects of immunosubunit deficiency in
development of T-cell transfer colitis. Thus we cannot exclude that
specific proteasome subtypes [23,24], present in single immuno-
subunit-deficient cells but lacking in double immunosubunit-
deficient cells, or the other way around, are responsible for the
discrepancy between effects of immunosubunit deficiency in colitis
induction in the two models. A more likely explanation however
lies in the involvement of different immune effector cells in DSS-
induced compared to T-cell transfer-induced colitis and perhaps
the differing roles of NFkB activation in these cell types. In DSS-
induced colitis, inflammation is driven primarily by leukocytes of
the innate immune system, such as monocyte-derived macrophag-
es, which are dependent on NFkB activation for cytokine
expression. Thus, delayed NFkB processing may modify the
cytokine environment in DSS-treated mice and thereby prevent
the onset of lead to modest inflammation at most. In T-cell
transfer-induced colitis, inflammation is mediated by activated
CD4+ T-cells. In T cells, NFkB activation plays a role only during
priming, since CD28-mediated costimulatory signals are depen-
dent on the NFkB pathway but once primed, T-cells secrete
cytokines mainly upon antigen-induced TCR stimulation. As
discussed above, b5i/LMP7-deficient T cells are activated in
inflammatory disease models (as well as infection models) and
secrete cytokines upon TCR engagement with quantities compa-
rable to those secreted by wt T cells [14,16], thus a possibly
delayed NFkB activation does not impair their function.
Taken together, we conclude that immunosubunit deficiency
may influence disease processes in different ways, depending on
the etiology of disease. Our data argue against any direct
attenuating effects on inflammatory CD4+ T-cells but, in contrary,
show that b2i/MECL-1&b5i/LMP7-deficiency enhances CD4+
T-cell-mediated inflammation in T-cell transfer-induced colitis.
Materials and Methods
Mice
C57BL/6 (B6), B6 RAG-12/2, B6 b5i/LMP72/2b2i/MECL-
12/2 [9,25,26] and B6 RAG-12/2b5i/LMP72/2b2i/MECL-12/
2 mice [24] were maintained by in-house breeding under specific
pathogen-free conditions or under standard conditions, in filter top
cages. All experiments were performed with age-matched mice.
Ethics Statement
All animal experiments were carried out in strict accordance
with the Dutch Animal Experimentation Act and EU directives
86/609/CEE and 2010/63/EU related to the protection of
vertebrate animals used for experimental or other scientific
purposes. The experimental protocols were approved by the
Committee on Animal Experiments of the University of Utrecht
(DEC 2012.II.02.029) and performed in the Central Laboratory
Animal Research Facility of the University of Utrecht, which has
AAALAC (Association for Assessment and Accreditation of
Laboratory Animal Care) accreditation.
T-cell Transfer Colitis Model
To induce colitis, CD4+ CD45RBhigh cells were FASC-purified
from the spleens of B6 wt and B6 b2i/MECL-12/2b5i/LMP72/2
donor mice, using a BD InfluxTM (BD Biosciences). A total of
46105 CD4+CD45RBhigh cells were injected intraperitoneally (i.p.)
in 200 ml PBS into B6 RAG-12/2 or B6 RAG-12/2b5i/LMP72/
2b2i/MECL-12/2 recipient mice. Mice were monitored for 6
weeks for clinical signs and body weight and then sacrificed.
Colons were flushed with 10% formalin to remove feces, fixed and
stored in 70% ethanol for H&E histopathology. Colitis develop-
ment was evaluated by histology by two independent experts in a
blinded fashion, with minor modifications from the protocol
described in [20]. In brief, inflammatory infiltrates, depletion of
goblet cells and epithelial hyperplasia were scored as specified in
Table 1. Scores for specific colon sections represent the sum of
scores for these different criteria. The overall histological score per
mouse colon is the average of individual scores for the proximal,
mid and distal colon segments.
Flow Cytometry and T-cell Stimulation
Spleens were passed through a 70 mm cell strainer to prepare
single cell suspensions, and erythrocytes were lysed by treatment
with ammonium chloride. Cells for T-cell transfer were stained
with anti-CD4 mAb (RM4-5, eBioScience) in the presence of Fc-
block, enriched using a BD InfluxTM (BD Biosciences) and then
were stained with anti-CD45RB (16A, BD Pharmingen) and anti-
CD25 (PC61, eBioscience) mAbs and resorted to obtain a
CD4+CD45RBhighCD252 population that was used for induction
of colitis. To analyze spleens of T-cell transferred mice, total cell
counts in single cell suspensions were determined and cell samples
then were stained for CD4 cell surface and intracellular FoxP3
expression (clone FJK-16S, eBioscience) according to manufac-
turer’s instructions. Cells were measured on a FACSCantoII (BD
Biosciences) and analyzed with FlowJo software (Tree Star). To
determine cytokine expression, splenocytes were stimulated with
or without anti-CD3 mAb (145.2C11, BD Pharmingen, 2 mg/ml)
for 4 h, pelleted and then stored at 220uC in TRIzol reagent
(Invitrogen, Breda, NL) prior to RNA purification.
Quantitative PCR
RNA was extracted from TRIzol stored samples as instructed
(Invitrogen, Breda, NL) and quantified using a Nanodrop ND-
1000 (Thermo Scientific, Etten-Leur, NL). 1 mg of total RNA was
reverse transcribed into cDNA synthesis using an iScript cDNA
Synthesis Kit (Bio-Rad Laboratories, Veenendaal, NL). TaqManH
Gene Expression Assays (Applied Biosystems, Austin, TX, USA)
were used for qRT-PCR amplification and expression of the
following genes was assessed: IL17a, IFNy, TNFa and IL10.
Relative expression of target genes was calculated using the Pfaffl
method with 18S rRNA as a reference gene.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism 4.00
(Graphpad Software, San Diego, CA) using Mann–Whitney U test
(+) to compare results between experimental groups. Significant
results are at P#0.05.
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Supporting Information
Figure S1 Representative histological colon sections.
Flow cytometry-sorted naı¨ve CD4+ T-cells of B6 (WT) or b2i/
MECL-12/2b5i/LMP72/2 (IS2/2) mice were transferred into
RAG12/2 or RAG12/2b2i/MECL-12/2b5i/LMP72/2
(IS2/2 x RAG12/2) mice and colitis development was
determined 6 weeks later by histological scoring of H&E stained
tissue samples (see Materials & Methods). Pictures were taken at
40x magnification. (A) Infiltrate in the lamina propria and
submucosa with multifocal loss of goblet cells and mild epithelial
hyperplasia; (B) Infiltrate in the lamina propria and submucosa
with focal loss of goblet cells and mild epithelial hyperplasia; (C)
Multifocal infiltration in the lamina propria with diminished
number of goblet cells and mild epithelial hyperplasia; (D) Evident
infiltration distending submucosal splace with depletion of goblet
cells and severe epithelial hyperplasia with crowding of mucosal
crypts; (E) Transmural infiltration with depletion of goblet cells
and severe hyperplasia; (F) Evident infiltration with loss of goblet
cells and severe epithelial hyperplasia; (G) Evident infiltration with
multifocal loss of goblet cells and few areas of epithelial
hyperplasia; (H) Multifocal infiltration in the lamina propria and
loss of goblet cells with severe hyperplasia and crowding of crypts;
(I) Multiple foci of inflammatory infiltrate and loss of goblet cells
and mild hyperplasia. (J) Transmural infiltration with diminished
goblet cells and mild hyperplasia; (K) Evident infiltration with
depletion of goblet cells and severe hyperplasia; (L) Evident
infiltrate in the lamina propria and submucosa with diminished
goblet cells and hyperplasia. Data are representative of two
independent experiments.
(PDF)
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